Details of the Drug

General Information of Drug (ID: DM23HCX)

Drug Name
Dextropropoxyphene
Synonyms
Algafan; Antalvic; Destropropossifene; Dextropropoxifeno; Dextropropoxyphen; Dextropropoxyphenum; Dextroproxifeno; Femadol; Levopropoxyphene; Propoxyphene; Proxagesic; Proxyphen; Destropropossifene [DCIT]; Dextroproxifeno [Spanish]; SK 65; D-Propoxyphene; Dextropropoxifeno [INN-Spanish]; Dextropropoxyphene[INN:BAN]; Dextropropoxyphenum [INN-Latin]; Bulk dextropropoxyphene (non-dosage forms); Alpha-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol propionate; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat; Alpha-D-4-Dimethylamino-3-methyl-1,2-diphenyl-2-butanol-propionat [German]; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-butanol propionate ester; Alpha-(+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane; [(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate; (+)-1,2-Diphenyl-2-propionoxy-3-methyl-4-dimethylaminobutane; (+)-4-Dimethylamino-1,2-diphenyl-3-methyl-2-propionyloxybutane; (1S,2R)-1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate; (D)-PROPOXYPHENE; (S)-alpha-(2-(Dimethylamino)-1-methylethyl)-alpha-phenylbenzeneethanol propanoate; 4-Dimethylamino-3-methyl-1,2-diphenyl-2-propoxybutane
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Approved [1], [2]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 339.5
Topological Polar Surface Area (xlogp) 4.2
Rotatable Bond Count (rotbonds) 9
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The clearance of drug is 2.6 L/min [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 6 - 12 hours [5]
Metabolism
The drug is metabolized via the hepatic [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 19.14682 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.24% [5]
Vd
The volume of distribution (Vd) of drug is 16 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0196 mg/mL [3]
Chemical Identifiers
Formula
C22H29NO2
IUPAC Name
[(2S,3R)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate
Canonical SMILES
CCC(=O)O[C@](CC1=CC=CC=C1)(C2=CC=CC=C2)[C@H](C)CN(C)C
InChI
InChI=1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1
InChIKey
XLMALTXPSGQGBX-GCJKJVERSA-N
Cross-matching ID
PubChem CID
10100
ChEBI ID
CHEBI:51173
CAS Number
469-62-5
DrugBank ID
DB00647
TTD ID
D0D4PB
INTEDE ID
DR0478
ACDINA ID
D00564

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Opioid receptor (OPR) TTN4QDT NOUNIPROTAC Agonist [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dextropropoxyphene
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Pentazocine DM1XBHS Major Additive CNS depression effects by the combination of Dextropropoxyphene and Pentazocine. Pain [MG30-MG3Z] [37]
Oxymorphone DM65AGJ Major Additive CNS depression effects by the combination of Dextropropoxyphene and Oxymorphone. Pain [MG30-MG3Z] [37]
Dezocine DMJDB0Y Major Additive CNS depression effects by the combination of Dextropropoxyphene and Dezocine. Pain [MG30-MG3Z] [37]
Flavoxate DMKV4NL Major Additive CNS depression effects by the combination of Dextropropoxyphene and Flavoxate. Pain [MG30-MG3Z] [37]
Nalbuphine DMOSQGU Major Additive CNS depression effects by the combination of Dextropropoxyphene and Nalbuphine. Pain [MG30-MG3Z] [37]
Hydrocodone DMQ2JO5 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Hydrocodone. Pain [MG30-MG3Z] [37]
Ziconotide DMSLJP4 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Ziconotide. Pain [MG30-MG3Z] [37]
⏷ Show the Full List of 7 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Dextropropoxyphene (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Dextropropoxyphene and Methylene blue. Acquired methaemoglobinaemia [3A93] [38]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Dextropropoxyphene and Repaglinide. Acute diabete complication [5A2Y] [39]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Dextropropoxyphene and Glibenclamide. Acute diabete complication [5A2Y] [39]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Dextropropoxyphene and Tolazamide. Acute diabete complication [5A2Y] [39]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Dextropropoxyphene and Nateglinide. Acute diabete complication [5A2Y] [39]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Dextropropoxyphene and Insulin-glulisine. Acute diabete complication [5A2Y] [40]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Dextropropoxyphene and Insulin-aspart. Acute diabete complication [5A2Y] [40]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Dextropropoxyphene and Glipizide. Acute diabete complication [5A2Y] [39]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Ivosidenib. Acute myeloid leukaemia [2A60] [41]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Midostaurin. Acute myeloid leukaemia [2A60] [42]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Idarubicin. Acute myeloid leukaemia [2A60] [42]
Daunorubicin DMQUSBT Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Daunorubicin. Acute myeloid leukaemia [2A60] [42]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Arn-509. Acute myeloid leukaemia [2A60] [43]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Gilteritinib. Acute myeloid leukaemia [2A60] [44]
Oliceridine DM6MDCF Major Additive CNS depression effects by the combination of Dextropropoxyphene and Oliceridine. Acute pain [MG31] [37]
Scopolamine DMOM8AL Major Additive CNS depression effects by the combination of Dextropropoxyphene and Scopolamine. Addictive disorder [6C50-6C5Z] [37]
Mepyramine DMB4SFH Major Additive CNS depression effects by the combination of Dextropropoxyphene and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [37]
Phenyltoloxamine DMKAEQW Major Additive CNS depression effects by the combination of Dextropropoxyphene and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [37]
Tripelennamine DMZBU15 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [37]
Galantamine DMEO794 Moderate Decreased metabolism of Dextropropoxyphene caused by Galantamine mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [45]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Dextropropoxyphene and Rivastigmine. Alzheimer disease [8A20] [46]
Donepezil DMIYG7Z Minor Decreased metabolism of Dextropropoxyphene caused by Donepezil mediated inhibition of CYP450 enzyme. Alzheimer disease [8A20] [47]
Metronidazole DMTIVEN Minor Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Metronidazole. Amoebiasis [1A36] [48]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Dextropropoxyphene and Ivabradine. Angina pectoris [BA40] [43]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Bepridil. Angina pectoris [BA40] [49]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Dronedarone. Angina pectoris [BA40] [49]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [50]
Methylphenobarbital DMDSWAG Major Additive CNS depression effects by the combination of Dextropropoxyphene and Methylphenobarbital. Anxiety disorder [6B00-6B0Z] [37]
Halazepam DMPFWO6 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Halazepam. Anxiety disorder [6B00-6B0Z] [37]
Chlormezanone DMTWUXR Major Decreased metabolism of Dextropropoxyphene caused by Chlormezanone mediated inhibition of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [37]
Oxazepam DMXNZM4 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Oxazepam. Anxiety disorder [6B00-6B0Z] [37]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Cilostazol. Arterial occlusive disease [BD40] [42]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Posaconazole. Aspergillosis [1F20] [42]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Dextropropoxyphene and Levalbuterol. Asthma [CA23] [51]
Terbutaline DMD4381 Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Terbutaline. Asthma [CA23] [51]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Dextropropoxyphene and Pirbuterol. Asthma [CA23] [51]
Salbutamol DMN9CWF Moderate Increased risk of ventricular arrhythmias by the combination of Dextropropoxyphene and Salbutamol. Asthma [CA23] [51]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Dextropropoxyphene and Formoterol. Asthma [CA23] [51]
Desipramine DMT2FDC Major Additive CNS depression effects by the combination of Dextropropoxyphene and Desipramine. Attention deficit hyperactivity disorder [6A05] [52]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Ofloxacin. Bacterial infection [1A00-1C4Z] [46]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [49]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Sparfloxacin. Bacterial infection [1A00-1C4Z] [53]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Gemifloxacin. Bacterial infection [1A00-1C4Z] [54]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Norfloxacin. Bacterial infection [1A00-1C4Z] [46]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Lomefloxacin. Bacterial infection [1A00-1C4Z] [42]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Telithromycin. Bacterial infection [1A00-1C4Z] [49]
Retigabine DMGNYIH Major Additive CNS depression effects by the combination of Dextropropoxyphene and Retigabine. Behcet disease [4A62] [37]
Cariprazine DMJYDVK Major Decreased metabolism of Dextropropoxyphene caused by Cariprazine mediated inhibition of CYP450 enzyme. Bipolar disorder [6A60] [37]
Loperamide DMOJZQ9 Moderate Additive CNS depression effects by the combination of Dextropropoxyphene and Loperamide. Bowel habit change [ME05] [43]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Eribulin. Breast cancer [2C60-2C6Y] [49]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Lapatinib. Breast cancer [2C60-2C6Y] [42]
Tamoxifen DMLB0EZ Major Decreased metabolism of Dextropropoxyphene caused by Tamoxifen mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [55]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [56]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Dextropropoxyphene and Olodaterol. Chronic obstructive pulmonary disease [CA22] [51]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Vilanterol. Chronic obstructive pulmonary disease [CA22] [51]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Dextropropoxyphene and Salmeterol. Chronic obstructive pulmonary disease [CA22] [51]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Dextropropoxyphene and Indacaterol. Chronic obstructive pulmonary disease [CA22] [51]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Arformoterol. Chronic obstructive pulmonary disease [CA22] [51]
Dihydrocodeine DMB0FWL Major Additive CNS depression effects by the combination of Dextropropoxyphene and Dihydrocodeine. Chronic pain [MG30] [37]
Levetiracetam DMTGDN8 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Levetiracetam. Chronic pain [MG30] [37]
Levomilnacipran DMV26S8 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Levomilnacipran. Chronic pain [MG30] [37]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Isoproterenol. Conduction disorder [BC63] [51]
Propofol DMB4OLE Moderate Additive CNS depression effects by the combination of Dextropropoxyphene and Propofol. Corneal disease [9A76-9A78] [57]
Ketamine DMT5HA4 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Ketamine. Corneal disease [9A76-9A78] [37]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Probucol. Coronary atherosclerosis [BA80] [42]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Clofazimine. Crohn disease [DD70] [58]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Mifepristone. Cushing syndrome [5A70] [46]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Pasireotide. Cushing syndrome [5A70] [46]
Ethanol DMDRQZU Major Additive CNS depression effects by the combination of Dextropropoxyphene and Ethanol. Cystitis [GC00] [59]
Sertraline DM0FB1J Major Additive CNS depression effects by the combination of Dextropropoxyphene and Sertraline. Depression [6A70-6A7Z] [37]
Trimipramine DM1SC8M Major Additive CNS depression effects by the combination of Dextropropoxyphene and Trimipramine. Depression [6A70-6A7Z] [52]
Cyclobenzaprine DM1YBRM Major Additive CNS depression effects by the combination of Dextropropoxyphene and Cyclobenzaprine. Depression [6A70-6A7Z] [37]
Nefazodone DM4ZS8M Major Additive CNS depression effects by the combination of Dextropropoxyphene and Nefazodone. Depression [6A70-6A7Z] [37]
Paroxetine DM5PVQE Major Additive CNS depression effects by the combination of Dextropropoxyphene and Paroxetine. Depression [6A70-6A7Z] [37]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Dextropropoxyphene and Selegiline. Depression [6A70-6A7Z] [38]
Vortioxetine DM6F1PU Major Additive CNS depression effects by the combination of Dextropropoxyphene and Vortioxetine. Depression [6A70-6A7Z] [37]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Dextropropoxyphene and Isocarboxazid. Depression [6A70-6A7Z] [38]
Milnacipran DMBFE74 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Milnacipran. Depression [6A70-6A7Z] [60]
Escitalopram DMFK9HG Major Additive CNS depression effects by the combination of Dextropropoxyphene and Escitalopram. Depression [6A70-6A7Z] [37]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Dextropropoxyphene and Tranylcypromine. Depression [6A70-6A7Z] [38]
Desvenlafaxine DMHD4PE Major Additive CNS depression effects by the combination of Dextropropoxyphene and Desvenlafaxine. Depression [6A70-6A7Z] [37]
OPC-34712 DMHG57U Major Additive CNS depression effects by the combination of Dextropropoxyphene and OPC-34712. Depression [6A70-6A7Z] [37]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Dextropropoxyphene and Phenelzine. Depression [6A70-6A7Z] [38]
Clomipramine DMINRKW Major Additive CNS depression effects by the combination of Dextropropoxyphene and Clomipramine. Depression [6A70-6A7Z] [52]
Trazodone DMK1GBJ Major Additive CNS depression effects by the combination of Dextropropoxyphene and Trazodone. Depression [6A70-6A7Z] [37]
Doxepin DMPI98T Major Additive CNS depression effects by the combination of Dextropropoxyphene and Doxepin. Depression [6A70-6A7Z] [52]
Esketamine DMVU687 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Esketamine. Depression [6A70-6A7Z] [60]
Mepenzolate DM8YU2F Moderate Additive CNS depression effects by the combination of Dextropropoxyphene and Mepenzolate. Digestive system disease [DE2Z] [61]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive CNS depression effects by the combination of Dextropropoxyphene and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [37]
Oxybutynine DMJPBAX Moderate Additive CNS depression effects by the combination of Dextropropoxyphene and Oxybutynine. Discovery agent [N.A.] [61]
Heroin diacetylmorphine DMDBWHY Major Additive CNS depression effects by the combination of Dextropropoxyphene and Heroin diacetylmorphine. Dissociative neurological symptom disorder [6B60] [37]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [46]
Meclizine DMS7T13 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Meclizine. Dizziness and giddiness [MB48] [37]
Diazepam DM08E9O Major Additive CNS depression effects by the combination of Dextropropoxyphene and Diazepam. Epilepsy/seizure [8A61-8A6Z] [37]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [37]
Primidone DM0WX6I Major Decreased metabolism of Dextropropoxyphene caused by Primidone mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [37]
Felbamate DM1V5ZS Major Additive CNS depression effects by the combination of Dextropropoxyphene and Felbamate. Epilepsy/seizure [8A61-8A6Z] [60]
Methsuximide DM6L5VO Major Additive CNS depression effects by the combination of Dextropropoxyphene and Methsuximide. Epilepsy/seizure [8A61-8A6Z] [37]
Gabapentin DM6T924 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Gabapentin. Epilepsy/seizure [8A61-8A6Z] [62]
Tiagabine DMKSQG0 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Tiagabine. Epilepsy/seizure [8A61-8A6Z] [37]
Phenacemide DMOHS9P Major Additive CNS depression effects by the combination of Dextropropoxyphene and Phenacemide. Epilepsy/seizure [8A61-8A6Z] [37]
Fosphenytoin DMOX3LB Major Additive CNS depression effects by the combination of Dextropropoxyphene and Fosphenytoin. Epilepsy/seizure [8A61-8A6Z] [37]
Brivaracetam DMSEPK8 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Brivaracetam. Epilepsy/seizure [8A61-8A6Z] [37]
Clonazepam DMTO13J Major Additive CNS depression effects by the combination of Dextropropoxyphene and Clonazepam. Epilepsy/seizure [8A61-8A6Z] [37]
Rufinamide DMWE60C Major Additive CNS depression effects by the combination of Dextropropoxyphene and Rufinamide. Epilepsy/seizure [8A61-8A6Z] [37]
Ethotoin DMXWOCP Major Additive CNS depression effects by the combination of Dextropropoxyphene and Ethotoin. Epilepsy/seizure [8A61-8A6Z] [37]
Phenobarbital DMXZOCG Major Additive CNS depression effects by the combination of Dextropropoxyphene and Phenobarbital. Epilepsy/seizure [8A61-8A6Z] [60]
Vigabatrin DMYT0OG Major Additive CNS depression effects by the combination of Dextropropoxyphene and Vigabatrin. Epilepsy/seizure [8A61-8A6Z] [37]
Cannabidiol DM0659E Major Additive CNS depression effects by the combination of Dextropropoxyphene and Cannabidiol. Epileptic encephalopathy [8A62] [37]
Dantrolene DM1D8XY Major Decreased metabolism of Dextropropoxyphene caused by Dantrolene mediated inhibition of CYP450 enzyme. Fever [MG26] [37]
Solifenacin DMG592Q Moderate Additive CNS depression effects by the combination of Dextropropoxyphene and Solifenacin. Functional bladder disorder [GC50] [61]
Mirabegron DMS1GYT Moderate Decreased metabolism of Dextropropoxyphene caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [63]
Tolterodine DMSHPW8 Moderate Additive CNS depression effects by the combination of Dextropropoxyphene and Tolterodine. Functional bladder disorder [GC50] [61]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Pentamidine. Fungal infection [1F29-1F2F] [42]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Ketoconazole. Fungal infection [1F29-1F2F] [42]
Propantheline DM2EN6G Moderate Additive antimotility effects by the combination of Dextropropoxyphene and Propantheline. Gastric ulcer [DA60] [61]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Sunitinib. Gastrointestinal stromal tumour [2B5B] [49]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Dextropropoxyphene and Procarbazine. Hodgkin lymphoma [2B30] [38]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Dextropropoxyphene caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [64]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [46]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [42]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Dextropropoxyphene caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [46]
Acebutolol DM0TI4U Moderate Decreased metabolism of Dextropropoxyphene caused by Acebutolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [65]
Nebivolol DM7F1PA Moderate Decreased metabolism of Dextropropoxyphene caused by Nebivolol mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [65]
Givosiran DM5PFIJ Moderate Decreased metabolism of Dextropropoxyphene caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [66]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Dextropropoxyphene caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [67]
Suvorexant DM0E6S3 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Suvorexant. Insomnia [7A00-7A0Z] [37]
Amobarbital DM0GQ8N Major Additive CNS depression effects by the combination of Dextropropoxyphene and Amobarbital. Insomnia [7A00-7A0Z] [37]
Ramelteon DM7IW9J Major Additive CNS depression effects by the combination of Dextropropoxyphene and Ramelteon. Insomnia [7A00-7A0Z] [37]
Flurazepam DMAL4G0 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Flurazepam. Insomnia [7A00-7A0Z] [37]
Triazolam DMETYK5 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Triazolam. Insomnia [7A00-7A0Z] [37]
Zaleplon DMGFWSM Major Additive CNS depression effects by the combination of Dextropropoxyphene and Zaleplon. Insomnia [7A00-7A0Z] [60]
Propiomazine DMKY8V1 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Propiomazine. Insomnia [7A00-7A0Z] [52]
Tasimelteon DMLOQ1V Major Additive CNS depression effects by the combination of Dextropropoxyphene and Tasimelteon. Insomnia [7A00-7A0Z] [37]
Paraldehyde DMOC1BX Major Additive CNS depression effects by the combination of Dextropropoxyphene and Paraldehyde. Insomnia [7A00-7A0Z] [60]
ITI-007 DMUQ1DO Major Additive CNS depression effects by the combination of Dextropropoxyphene and ITI-007. Insomnia [7A00-7A0Z] [37]
Quazepam DMY4D87 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Quazepam. Insomnia [7A00-7A0Z] [37]
Estazolam DMZGXUM Major Additive CNS depression effects by the combination of Dextropropoxyphene and Estazolam. Insomnia [7A00-7A0Z] [37]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Dextropropoxyphene and Polyethylene glycol. Irritable bowel syndrome [DD91] [49]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Dextropropoxyphene and Phenolphthalein. Irritable bowel syndrome [DD91] [46]
Clidinium DMUMQZ0 Moderate Additive antimotility effects by the combination of Dextropropoxyphene and Clidinium. Irritable bowel syndrome [DD91] [61]
Dicyclomine DMZSDGX Moderate Additive CNS depression effects by the combination of Dextropropoxyphene and Dicyclomine. Irritable bowel syndrome [DD91] [61]
Remimazolam DMLVSYX Major Additive CNS depression effects by the combination of Dextropropoxyphene and Remimazolam. Labour/delivery anaesthesia complication [JB0C] [37]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Dextropropoxyphene caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [43]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Crizotinib. Lung cancer [2C25] [41]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Ceritinib. Lung cancer [2C25] [46]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Dextropropoxyphene caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [68]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Osimertinib. Lung cancer [2C25] [41]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Selpercatinib. Lung cancer [2C25] [69]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Lumefantrine. Malaria [1F40-1F45] [46]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Halofantrine. Malaria [1F40-1F45] [46]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Hydroxychloroquine. Malaria [1F40-1F45] [70]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Primaquine. Malaria [1F40-1F45] [42]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [43]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Vemurafenib. Melanoma [2C30] [49]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and LGX818. Melanoma [2C30] [71]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Dextropropoxyphene and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [72]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Dextropropoxyphene and Lasmiditan. Migraine [8A80] [73]
Flibanserin DM70DTN Major Additive CNS depression effects by the combination of Dextropropoxyphene and Flibanserin. Mood disorder [6A60-6E23] [37]
Midazolam DMXOELT Major Additive CNS depression effects by the combination of Dextropropoxyphene and Midazolam. Mood/affect symptom [MB24] [37]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Panobinostat. Multiple myeloma [2A83] [74]
Thalidomide DM70BU5 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Thalidomide. Multiple myeloma [2A83] [60]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Dextropropoxyphene and Siponimod. Multiple sclerosis [8A40] [46]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Dextropropoxyphene and Fingolimod. Multiple sclerosis [8A40] [49]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Dextropropoxyphene and Ozanimod. Multiple sclerosis [8A40] [75]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Romidepsin. Mycosis fungoides [2B01] [42]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Dextropropoxyphene caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [76]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Nilotinib. Myeloproliferative neoplasm [2A20] [49]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Dasatinib. Myeloproliferative neoplasm [2A20] [46]
Prasugrel DM7MT6E Moderate Altered absorption of Dextropropoxyphene due to GI dynamics variation caused by Prasugrel. Myocardial infarction [BA41-BA43] [46]
Phenindamine DMDTC7R Major Additive CNS depression effects by the combination of Dextropropoxyphene and Phenindamine. Nasopharyngitis [CA00] [37]
Dimenhydrinate DM264B3 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Dimenhydrinate. Nausea/vomiting [MD90] [37]
Promethazine DM6I5GR Major Additive CNS depression effects by the combination of Dextropropoxyphene and Promethazine. Nausea/vomiting [MD90] [52]
Rolapitant DM8XP26 Moderate Decreased metabolism of Dextropropoxyphene caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [41]
Cyclizine DM9G7BS Major Additive CNS depression effects by the combination of Dextropropoxyphene and Cyclizine. Nausea/vomiting [MD90] [37]
Metoclopramide DMFA5MY Major Additive CNS depression effects by the combination of Dextropropoxyphene and Metoclopramide. Nausea/vomiting [MD90] [37]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Dolasetron. Nausea/vomiting [MD90] [46]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Ondansetron. Nausea/vomiting [MD90] [42]
Bupropion DM5PCS7 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Bupropion. Nicotine use disorder [6C4A] [37]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Entrectinib. Non-small cell lung cancer [2C25] [43]
Sibutramine DMFJTDI Major Additive CNS depression effects by the combination of Dextropropoxyphene and Sibutramine. Obesity [5B80-5B81] [37]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Levomethadyl Acetate. Opioid use disorder [6C43] [43]
Lofexidine DM1WXA6 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Lofexidine. Opioid use disorder [6C43] [37]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Rucaparib. Ovarian cancer [2C73] [42]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Triclabendazole. Parasitic worm infestation [1F90] [42]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Dextropropoxyphene and Safinamide. Parkinsonism [8A00] [77]
Pergolide DM14MAE Major Additive CNS depression effects by the combination of Dextropropoxyphene and Pergolide. Parkinsonism [8A00] [37]
Opicapone DM1BKA6 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Opicapone. Parkinsonism [8A00] [37]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Dextropropoxyphene and Rasagiline. Parkinsonism [8A00] [38]
Biperiden DME78OA Moderate Additive CNS depression effects by the combination of Dextropropoxyphene and Biperiden. Parkinsonism [8A00] [78]
Levodopa DMN3E57 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Levodopa. Parkinsonism [8A00] [37]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Pimavanserin. Parkinsonism [8A00] [41]
Bromocriptine DMVE3TK Major Additive CNS depression effects by the combination of Dextropropoxyphene and Bromocriptine. Parkinsonism [8A00] [37]
Apomorphine DMX38HQ Major Additive CNS depression effects by the combination of Dextropropoxyphene and Apomorphine. Parkinsonism [8A00] [37]
Methylscopolamine DM5VWOB Moderate Additive antimotility effects by the combination of Dextropropoxyphene and Methylscopolamine. Peptic ulcer [DA61] [61]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Famotidine. Peptic ulcer [DA61] [46]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Macimorelin. Pituitary gland disorder [5A60-5A61] [41]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Lefamulin. Pneumonia [CA40] [41]
Ritodrine DM4V6RL Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Ritodrine. Preterm labour/delivery [JB00] [51]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Degarelix. Prostate cancer [2C82] [43]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Dextropropoxyphene caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [41]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Nilutamide. Prostate cancer [2C82] [43]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Enzalutamide. Prostate cancer [2C82] [43]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Relugolix. Prostate cancer [2C82] [43]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Bicalutamide. Prostate cancer [2C82] [43]
Tamsulosin DM5QF9V Moderate Decreased metabolism of Dextropropoxyphene caused by Tamsulosin mediated inhibition of CYP450 enzyme. Prostate hyperplasia [GA90] [79]
Levomepromazine DMIKFEL Major Additive CNS depression effects by the combination of Dextropropoxyphene and Levomepromazine. Psychotic disorder [6A20-6A25] [80]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Gatifloxacin. Respiratory infection [CA07-CA4Z] [81]
Neupro DMHEAB1 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Neupro. Restless legs syndrome [7A80] [37]
Quetiapine DM1N62C Major Additive CNS depression effects by the combination of Dextropropoxyphene and Quetiapine. Schizophrenia [6A20] [37]
Mesoridazine DM2ZGAN Major Additive CNS depression effects by the combination of Dextropropoxyphene and Mesoridazine. Schizophrenia [6A20] [52]
Thioridazine DM35M8J Major Decreased metabolism of Dextropropoxyphene caused by Thioridazine mediated inhibition of CYP450 enzyme. Schizophrenia [6A20] [82]
Aripiprazole DM3NUMH Major Additive CNS depression effects by the combination of Dextropropoxyphene and Aripiprazole. Schizophrenia [6A20] [37]
Iloperidone DM6AUFY Major Additive CNS depression effects by the combination of Dextropropoxyphene and Iloperidone. Schizophrenia [6A20] [60]
Paliperidone DM7NPJS Major Additive CNS depression effects by the combination of Dextropropoxyphene and Paliperidone. Schizophrenia [6A20] [37]
Perphenazine DMA4MRX Major Additive CNS depression effects by the combination of Dextropropoxyphene and Perphenazine. Schizophrenia [6A20] [52]
Molindone DMAH70G Major Additive CNS depression effects by the combination of Dextropropoxyphene and Molindone. Schizophrenia [6A20] [37]
Thiothixene DMDINC4 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Thiothixene. Schizophrenia [6A20] [37]
Trifluoperazine DMKBYWI Major Additive CNS depression effects by the combination of Dextropropoxyphene and Trifluoperazine. Schizophrenia [6A20] [52]
Risperidone DMN6DXL Major Additive CNS depression effects by the combination of Dextropropoxyphene and Risperidone. Schizophrenia [6A20] [37]
Asenapine DMSQZE2 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Asenapine. Schizophrenia [6A20] [37]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Pimozide. Schizophrenia [6A20] [43]
Fentanyl DM8WAHT Major Decreased metabolism of Dextropropoxyphene caused by Fentanyl mediated inhibition of CYP450 enzyme. Sensation disturbance [MB40] [37]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Vardenafil. Sexual dysfunction [HA00-HA01] [42]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and LEE011. Solid tumour/cancer [2A00-2F9Z] [49]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [46]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [43]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [42]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Pitolisant. Somnolence [MG42] [43]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [42]
Brilinta DMBR01X Moderate Altered absorption of Dextropropoxyphene due to GI dynamics variation caused by Brilinta. Thrombosis [DB61-GB90] [46]
Clopidogrel DMOL54H Moderate Altered absorption of Dextropropoxyphene due to GI dynamics variation caused by Clopidogrel. Thrombosis [DB61-GB90] [46]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Lenvatinib. Thyroid cancer [2D10] [42]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Cabozantinib. Thyroid cancer [2D10] [43]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Papaverine. Tonus and reflex abnormality [MB47] [83]
Tizanidine DMR2IQ4 Major Additive CNS depression effects by the combination of Dextropropoxyphene and Tizanidine. Tonus and reflex abnormality [MB47] [37]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Tacrolimus. Transplant rejection [NE84] [42]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Dextropropoxyphene and Tolbutamide. Type 2 diabetes mellitus [5A11] [39]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Dextropropoxyphene and Chlorpropamide. Type 2 diabetes mellitus [5A11] [39]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Dextropropoxyphene and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [40]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Dextropropoxyphene and Insulin degludec. Type-1/2 diabete [5A10-5A11] [40]
Methdilazine DMAUHQX Major Additive CNS depression effects by the combination of Dextropropoxyphene and Methdilazine. Vasomotor/allergic rhinitis [CA08] [52]
Carbinoxamine DMCT31R Major Decreased metabolism of Dextropropoxyphene caused by Carbinoxamine mediated inhibition of CYP450 enzyme. Vasomotor/allergic rhinitis [CA08] [37]
Trimeprazine DMEMV9D Major Additive CNS depression effects by the combination of Dextropropoxyphene and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [52]
Brompheniramine DMFOVSD Major Additive CNS depression effects by the combination of Dextropropoxyphene and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [37]
Azatadine DMZ80SB Major Additive CNS depression effects by the combination of Dextropropoxyphene and Azatadine. Vasomotor/allergic rhinitis [CA08] [37]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Procainamide. Ventricular tachyarrhythmia [BC71] [49]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Propafenone. Ventricular tachyarrhythmia [BC71] [42]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Flecainide. Ventricular tachyarrhythmia [BC71] [42]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Dextropropoxyphene and Amiodarone. Ventricular tachyarrhythmia [BC71] [49]
⏷ Show the Full List of 250 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
D&C red no. 33 E00261 19116 Colorant
Potassium chloride E00074 4873 Tonicity agent
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd E00585 56841934 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hypromellose E00634 Not Available Coating agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 14 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Propoxyphene 65 mg capsule 65 mg Oral Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7593).
2 Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Nov-Dec;39(9):787-9.
3 BDDCS applied to over 900 drugs
4 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 CYP3A4 mediates dextropropoxyphene N-demethylation to nordextropropoxyphene: human in vitro and in vivo studies and lack of CYP2D6 involvement. Xenobiotica. 2004 Oct;34(10):875-87.
9 Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes. Eur J Clin Pharmacol. 1997;52(1):41-7.
10 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
20 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
21 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
22 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
23 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
24 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
25 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
26 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
27 Methadone treatment and its dangers. Medicina (Kaunas). 2009;45(5):419-25.
28 The mu1 and mu2 opioid receptor binding of ketobemidone, norketobemidone and 3-dimethylamino-1,1-diphenylbutene. Pharmacol Toxicol. 1996 Aug;79(2):103-4.
29 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7094).
30 mu-opioid receptor-stimulated synthesis of reactive oxygen species is mediated via phospholipase D2. J Neurochem. 2009 Aug;110(4):1288-96.
31 An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008 Feb;65(2):135-44.
32 Comparison of the effects of dextromethorphan, dextrorphan, and levorphanol on the hypothalamo-pituitary-adrenal axis. J Pharmacol Exp Ther. 2004 May;309(2):515-22.
33 Functional characterization of a sigma receptor and its gene expression by haloperidol. Nippon Yakurigaku Zasshi. 1999 Jul;114(1):61-8.
34 Unconditioned behavioral effects of the powerful kappa-opioid hallucinogen salvinorin A in nonhuman primates: fast onset and entry into cerebrospin... J Pharmacol Exp Ther. 2009 Feb;328(2):588-97.
35 Actions of tilidine and nortilidine on cloned opioid receptors. Eur J Pharmacol. 2005 Jan 4;506(3):205-8.
36 Affinities of dihydrocodeine and its metabolites to opioid receptors. Pharmacol Toxicol. 2002 Aug;91(2):57-63.
37 Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
38 Gillman PK "Possible serotonin syndrome with moclobemide and pethidine." Med J Aust 162 (1995): 554. [PMID: 7776924]
39 Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
40 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
41 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
42 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
43 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
44 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
45 Product Information. Reminyl (galantamine) Janssen Pharmaceuticals, Titusville, NJ.
46 Cerner Multum, Inc. "Australian Product Information.".
47 Product Information. Aricept (donepezil). Pfizer US Pharmaceuticals, New York, NY.
48 Giannini AJ, DeFrance DT "Metronidazole and alcohol: potential for combinative abuse." J Toxicol Clin Toxicol 20 (1983): 509-15. [PMID: 6668631]
49 Canadian Pharmacists Association.
50 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
51 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
52 Abernethy DR, Greenblatt DJ, Steel K, Shader RI "Impairment of hepatic drug oxidation by propoxyphene." Ann Intern Med 97 (1982): 223-4. [PMID: 7103282]
53 Dupont H, Timsit JF, Souweine B, Gachot B, Wolff M, Regnier B "Torsades de pointe probably related to sparfloxacin." Eur J Clin Microbiol Infect Dis 15 (1996): 350-1. [PMID: 8781892]
54 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
55 Goetz MP, Rae JM, Suman VJ, et al. "Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes." J Clin Oncol 23 (2005): 9312-8. [PMID: 16361630]
56 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
57 McClune S, McKay AC, Wright PM, et al "Synergistic interaction between midazolam and propofol." Br J Anaesth 69 (1992): 240-5. [PMID: 1389840]
58 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
59 Product Information. Darvon (propoxyphene). Lilly, Eli and Company, Indianapolis, IN.
60 Abernethy DR, Greenblatt DJ, Morse DS, Shader RI "Interaction of propoxyphene with diazepam, alprazolam and lorazepam." Br J Clin Pharmacol 19 (1985): 51-7. [PMID: 2858217]
61 Product Information. Exalgo (hydromorphone). Covidien, Mansfield, MA.
62 Eipe N, Penning J "Postoperative respiratory depression associated with pregabalin: a case series and a preoperative decision algorithm." Pain Res Manag 16 (2011): 353-6. [PMID: 22059207]
63 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
64 Bailey DG, Dresser GK "Natural products and adverse drug interactions." Can Med Assoc J 170 (2004): 1531-2. [PMID: 15136542]
65 Janku I, Perlik F, Tkaczykova M, Brodanova M "Disposition kinetics and concentration-effect relationship of metipranolol in patients with cirrhosis and healthy subjects." Eur J Clin Pharmacol 42 (1992): 337-40. [PMID: 1349528]
66 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
67 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
68 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
69 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
70 Product Information. Hydroxychloroquine Sulfate (hydroxychloroquine). Prasco Laboratories, Cincinnati, OH.
71 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
72 Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
73 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
74 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
75 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
76 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
77 Product Information. Eldepryl (selegiline). Somerset Pharmaceuticals Inc, Tampa, FL.
78 Product Information. Artane (trihexyphenidyl). Lederle Laboratories, Wayne, NJ.
79 Franco-Salinas G, de la Rosette JJ, Michel MC "Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations." Clin Pharmacokinet 49 (2010): 177-88. [PMID: 20170206]
80 Shorr RI, Griffin MR, Daugherty JR, Ray WA "Opioid analgesics and the risk of hip fracture in the elderly: codeine and propoxyphene." J Gerontol 47 (1992): m111-5. [PMID: 1624693]
81 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
82 Carrillo JA, Ramos SI, Herraiz AG, Llerena A, Agundez JAG, Berecz R, Duran M, Benitez J "Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients." J Clin Psychopharmacol 19 (1999): 494-9. [PMID: 10587283]
83 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]